Medindia LOGIN REGISTER
Medindia
Advertisement

Pharsight to Present at ROeS Seminar in Bern, Switzerland on September 10 & 11, 2007

Tuesday, September 4, 2007 General News
Advertisement
MOUNTAIN VIEW, Calif., Sept. 4 PharsightCorporation (OTC Bulletin Board: PHST), a leading provider of software andstrategic services for optimizing clinical drug development, today announcedthat Pharsight senior scientists will deliver two presentations tobiopharmaceutical industry statisticians attending the annual ROeS Seminar(Austrian-Swiss Region of the International Biometric Society), to be held inBern, Switzerland on September 9-13, 2007. Andreas Krause, Ph.D., seniorbiostat-istician, Strategic Consulting Services, will present a model-basedapproach to assess clinical study data for potentially confounding effects;Klaas Prins, Ph.D., senior scientist, Strategic Consulting Services, willpresent methods for extracting and integrating public-source scientificliterature in modeling and simulation analyses.
Advertisement

Drs. Krause and Prins will present applied case studies at two ROeSseminar sessions, each of which will provide a forum for pharmaceuticalscientists from industry and academia to have a collaborative exchange onmodel-based approaches. Pharsight's two presentations are:
Advertisement

Additional information can be found at http://www.meduniwien.ac.at/ROeS/

"Model-based drug development continues to show value for optimizing drugtherapy and for improving the confidence of drug development decisions," saidShawn O'Connor, president, CEO, and chairman of Pharsight. "Drug developmentcan benefit from the application of novel statistical methods and quantitativemodels to simulate expected clinical responses of new compounds, to supportcritical program strategies and to enhance study design decisions. Pharsightis pleased to participate at the annual ROeS Seminar, and to exchangeinformation with industry colleagues on the strategic use of modeling andsimulation."

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products andservices that enable pharmaceutical and biotechnology companies to achievesignificant and enduring improvements in the development and use oftherapeutic products. The company's goal is to help customers reduce the time,cost and risk of drug development, as well as optimize the post-approvalmarketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug developmentsuccess: strong decision-making. By adopting the Pharsight approach, customersacquire a new decision-making process with the potential to systematicallyimprove every level and phase of their business and scientific processes.Pharsight is headquartered in Mountain View, California. Information aboutPharsight is available at http://www.pharsight.com.Registered Trademarks and Trademarks

Pharsight is a registered trademark of Pharsight Corporation.-- September 10: Modeling and simulation to adjust p-values in presence of a regression to the mean effect. Dr. Krause will present this case study as part of a dedicated conference session on selection procedures and bias. The session will include applied examples of statistical methods to enable model-based drug development, and will describe research on how modeling and simulation has been used to analyze and monitor clinical information. -- September 11: Modeling and simulation using metadata: away from inventing the wheel again. Dr. Prins will present this case study as part of a dedicated conference session on methods in meta analysis. The session will include applied examples of modeling and simulation in several therapeutic areas, and will describe research on how models based on subject-level data and summary trial data have been used to predict drug candidate performance, capture development knowledge, and support the design of future clinical studies.

SOURCE Pharsight Corporation
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close